Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 49 of 172 for:    pertuzumab

Her2-positive Lung Cancer Treated With Dedicated Drug (R2D2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03845270
Recruitment Status : Recruiting
First Posted : February 19, 2019
Last Update Posted : September 2, 2019
Sponsor:
Information provided by (Responsible Party):
Intergroupe Francophone de Cancerologie Thoracique

Brief Summary:
HER2 (erbB-2/neu) is a member of the erbB receptor tyrosine kinase family. ERBB2 gene which encodes human epidermal growth factor 2 (HER2) is a major proliferative driver activating downstream signaling through PI3K-AKT and MEK-ERK. HER2 overexpression or gene amplification is associated with sensitivity to trastuzumab and lapatinib in breast cancer. Among actual lung cancer biomarker, HER2 remains apart. HER2 involvement is known for a long time but clinical research has been stopped for many years since the first clinical trials in unselected patients were negative. Recently trastuzumab + pertuzumab + docetaxel has been tested for first-line treatment of HER2-positive metastatic breast cancer (CLEOPATRA trial). Analysis of the primary end point showed that patients who received pertuzumab, trastuzumab, and docetaxel (pertuzumab group) had a significantly longer median progression-free survival, as assessed by independent reviewers an did those who received placebo, trastuzumab, and docetaxel (control group) (hazard ratio favoring the pertuzumab group, 0.62). There is thus a strong rational for treating HER2 mutated lung cancer patient with these drugs.

Condition or disease Intervention/treatment Phase
Non Small Cell Lung Cancer Metastatic Non Small Cell Lung Cancer Stage III HER2 Gene Mutation Drug: pertuzumab + trastuzumab + docetaxel Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Trial of Trastuzumab in Combination With Pertuzumab in Pretreated Patients With Non-small Cell Lung Cancer (NSCLC) Harboring a Her2 Mutation and Receiving Docetaxel
Actual Study Start Date : May 17, 2019
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : March 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: pertuzumab + trastuzumab + docetaxel
Cycle 1 : D1 : pertuzumab 840 mg, D2 : trastuzumab 8 mg/kg + docetaxel 75 mg/m² Subsequent cycle : D1 : pertuzumab 420 mg + trastuzumab 6 mg/kg + docetaxel 75 mg/m²
Drug: pertuzumab + trastuzumab + docetaxel
Cycle 1 : D1 : pertuzumab 840 mg, D2 : trastuzumab 8 mg/kg + docetaxel 75 mg/m² Subsequent cycle : D1 : pertuzumab 420 mg + trastuzumab 6 mg/kg + docetaxel 75 mg/m²




Primary Outcome Measures :
  1. Objective Response Rate [ Time Frame: 6 weeks (confirmation needed at 12 weeks) ]
    Percentage of patient with confirmed objective response rate with RECIST 1.1


Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: About 24 months ]
    Time from enrollment until death due to any cause

  2. Progression-free survival [ Time Frame: About 24 months ]
    time from enrollment to first observation of progression (according to RECIST v1.1) or date of death (from any cause)

  3. Duration of response [ Time Frame: About 24 months ]
    Time from documentation of tumor response to disease progression.

  4. Incidence, type and severity of non-serious and serious adverse event [ Time Frame: About 24 months ]

Other Outcome Measures:
  1. Correlation between OR, PFS, and HER2 mutation kinetic on cfDNA [ Time Frame: About 24 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient having signed an informed consent form
  2. Histologically or cytologically confirmed NSCLC (per 2015 8th edition TNM classification)
  3. Not suitable for radiation, inoperable stage III or stage IV
  4. HER2 exon 20 mutation or insertion among which: in-frame insertions in exon 20 between codons 775 and 881 including the 12bp insertion with a duplication / insertion of 4 amino acids (YVMA) at codon 775, the 3bp insertion with a complex insertion-substitution G776>VC and point mutations L755S and G776C. Other mutation/insertion should be discussed with the PI. Analysis must be performed in INCa-labelled laboratories or platforms according to a validated procedure.
  5. Prior treatment with at least one regimen of platinum-based chemotherapy with documented disease progression.

    Note: taxanes are allowed provided that no grade >2 associated adverse event occurred.

  6. Presence of at least one lesion that can be measured by CT scan (RECIST v1.1)
  7. Age ≥ 18 years
  8. Adequate organ function, as evidenced by the following laboratory results:

    ANC > 1500 cells/mm3 Platelet count > 100,000 cells/mm3 Hemoglobin > 9.0 g/dL Patients are allowed to receive transfused RBC to achieve this level. Total bilirubin ≤ 1.5 × ULN, except in patients with previously documented Gilbert's syndrome, in which case the direct bilirubin should be less than or equal to the ULN SGOT and SGPT ≤ 2.5 × ULN Alkaline phosphatase ≤ 2.5 × ULN, Alkaline phosphatase < 5×ULN and SGOT and SGPT < 5×ULN for patients with hepatic and/or bone metastases Clearance creatinine ≥ 30 mL/min INR and aPTT ≤ 1.5 x ULN This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose.

  9. WHO performance index of 0, 1 or 2
  10. LVEF ≥ 50% measured by ECHO
  11. Patient who is capable, according to the investigator, of complying with the study's requirements and restrictions
  12. Estimated life expectancy > 3 months
  13. A female is eligible to enter and participate in this study if she is of:

    Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who has undergone:

    • Hysterectomy.
    • Bilateral oophorectomy (ovariectomy).
    • Bilateral tubal ligation.
    • Or who is post-menopausal:
    • Patients not using hormone replacement therapy (HRT) must have experienced total cessation of menses for ≥1 year and be greater than 45 years in age, OR, in questionable cases, have a follicle stimulating hormone value >40 mIU/mL and an estradiol value <40 pg/mL (<140 pmol/L).
    • Patients must discontinue HRT prior to study enrolment due to the potential for inhibition of cytochrome enzymes that metabolize estrogens and progestins. For most forms of HRT, at least 2 4 weeks must elapse between the cessation of HRT and determination of menopausal status; length of this interval depends on the type and dosage of HRT. If a female subject is determined not to be post-menopausal, they must use adequate contraception, as defined immediately below.

    Childbearing potential, including any female who has had a negative serum pregnancy test within 2 weeks prior to the first dose of study treatment, preferably as close to the first dose as possible, and agrees to use adequate contraception during the study and for at least 7 months after the last dose of investigational product. Contraceptive methods acceptable to IFCT, when used consistently and in accordance with both the product label and the instructions of the physician, are as follow:

    • An intrauterine device with a documented failure rate of less than 1% per year.
    • Vasectomized partner who is sterile prior to the female subject's entry and is the sole sexual partner for that female.
    • Complete abstinence from sexual intercourse for 14 days before exposure to investigational product, through the dosing period, and for at least 7 months after the last dose of investigational product.
    • Double-barrier contraception (condom with spermicidal jelly, foam suppository or film; diaphragm with spermicide; or male condom and diaphragm with spermicide).

    Note: Oral contraceptives are not reliable due to potential drug drug interactions.

  14. Female patients who are lactating should discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period and for 15 days following the last dose of study drug.
  15. A male with a female partner of childbearing potential is eligible to enter and participate in the study if he uses a barrier method of contraception or abstinence during the study and for at least 7 months after the last dose of investigational product.
  16. Patient will be eligible for inclusion in this study only if either affiliated to or a beneficiary of social security insurance.

Exclusion Criteria:

  1. History of cancer except cancer dating from over two years ago and considered to be cured, appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma and stage I uterine cancer.
  2. Any approved anti-cancer therapy ≤ 21 days before enrollment. Note: TKIs approved for the treatment of NSCLC must be discontinued ≥ 7 days prior to the first study treatment on Cycle 1, Day 1. (The baseline scan must be completed after discontinuation of TKIs).
  3. Patients with concomitant EGFR, ALK, ROS1, MET, BRAF and KRAS mutation. Other molecular co-alterations should be discussed with IFCT before patient's enrollment.
  4. Previous treatment with an anti-HER2 agent.
  5. Any other investigational therapy ≤ 28 days before inclusion
  6. Previous irradiation <14 days before enrollment.
  7. Brain metastases that are symptomatic, or require any radiation, surgery, or corticosteroid therapy to control symptoms from brain metastases within 4 weeks before enrollment. Asymptomatic brain metastases with a fixed dose of steroids for at least 2 weeks are eligible.
  8. Carcinomatous meningitis
  9. History of intolerance (including Grade 3 or 4 infusion reaction) or hypersensitivity to trastuzumab, pertuzumab or docetaxel or murine proteins or one of the excipients
  10. Pregnancy and breast-feeding
  11. Any evidence of severe or uncontrolled systemic disease. (E.g. unstable or uncompensated respiratory, cardiac, hepatic, or renal disease) or other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study.
  12. Evidence of active pneumonitis during screening
  13. Current unstable ventricular arrhythmia requiring treatment, history of symptomatic congestive heart failure (CHF; New York Heart Association [NYHA] Classes II−IV) and history of myocardial infarction or unstable angina within 6 months before enrollment.
  14. Unresolved toxicity grade > 2 from previous anti-tumor treatments

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03845270


Locations
Layout table for location information
France
CHU Besançon Recruiting
Besançon, France
Contact: Virginie WESTEEL       contact@ifct.fr   
CHU de Bordeaux Recruiting
Bordeaux, France
Contact: Charlotte DOMBLIDES, MD       contact@ifct.fr   
Caen - CHU Côte de Nacre Recruiting
Caen, France, 14000
Contact: Jeannick MADELAINE, Dr       contact@ifct.fr   
Clermont-Ferrand - CHU Recruiting
Clermont-Ferrand, France
Contact: Patrick MERLE, MD       contact@ifct.fr   
Principal Investigator: Patrick MERLE, MD         
CHI Créteil Recruiting
Créteil, France
Contact: Isabelle MONNET       contact@ifct.fr   
CHRU Grenoble Recruiting
Grenoble, France
Contact: Denis MORO-SIBILOT       contact@ifct.fr   
Centre Hospitalier - Pneumologie Recruiting
Le Mans, France, 72000
Contact: François Pinquié, Dr       contact@ifct.fr   
Lyon - URCOT Recruiting
Lyon, France
Contact: Claire LAFITTE, MD       contact@ifct.fr   
Hôpital Nord APHM Recruiting
Marseille, France
Contact: Fabrice BARLESI, Pr       contact@ifct.fr   
Montpellier - CHRU Recruiting
Montpellier, France, 34295
Contact: Jean-Louis PUJOL, Pr       contact@ifct.fr   
CHU de Nantes Recruiting
Nantes, France
Contact: Jaafar BENNOUNA, MD, PhD       contact@ifct.fr   
Nice CLCC Recruiting
Nice, France
Contact: Josiane OTTO, Dr       contact@ifct.fr   
AP-HP Hopital Tenon - Pneumologie Recruiting
Paris, France, 75020
Contact: Jacques Cadranel, Pr    +33.1.56.01.65.31    contact@ifct.fr   
Principal Investigator: Jacques Cadranel, pr         
AP-HP Hôpital Bichat Recruiting
Paris, France
Contact: Gérard Zalcman, PhD       contact@ifct.fr   
Rennes - CHU Recruiting
Rennes, France, 35033
Contact: Hervé LENA, Dr       contact@ifct.fr   
CHU Strasbourg Recruiting
Strasbourg, France
Contact: François-Roger VANEL       contact@ifct.fr   
CHU Toulouse Recruiting
Toulouse, France
Contact: Julien MAZIERES, Pr       contact@ifct.fr   
Gustave Roussy Recruiting
Villejuif, France
Contact: Benjamin BESSE, Dr       contact@ifct.fr   
Sponsors and Collaborators
Intergroupe Francophone de Cancerologie Thoracique

Additional Information:
Layout table for additonal information
Responsible Party: Intergroupe Francophone de Cancerologie Thoracique
ClinicalTrials.gov Identifier: NCT03845270     History of Changes
Other Study ID Numbers: IFCT-1703
First Posted: February 19, 2019    Key Record Dates
Last Update Posted: September 2, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Intergroupe Francophone de Cancerologie Thoracique:
IFCT
NSCLC
HER2
Additional relevant MeSH terms:
Layout table for MeSH terms
Pertuzumab
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Docetaxel
Trastuzumab
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological